Not finding it? Sign in to also search OpenAlex live.
-
Model-informed development of a cost-saving dosing regimen for enfortumab vedotin2025 Cancer Chemotherapy and Pharmacology article Medicine Pharmaceutical studies and practices Open access
Amy Rieborn, Dirk Jan A. R. Moes, Jeroen J. M. A. Hendrikx, Michiel S. van der Heijden, Mira D. Franken, Tom van der Hulle, +5 more
5citations -
How to Dose Vancomycin in Overweight and Obese Patients with Varying Renal (Dys)function in the Novel Era of AUC 400–600 mg·h/L-Targeted Dosing2023 Clinical Pharmacokinetics article Medicine Antibiotics Pharmacokinetics and Efficacy Open access
Tan Zhang, Elke H. J. Krekels, Cornelis Smit, Eric P.A. van Dongen, Roger J. M. Brüggemann, Catherijne A. J. Knibbe
13citations -
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial2022 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access
Daniela Manno, Agnes Bangura, Frank Baiden, A Kamara, Philip Ayieko, J A Kallon, +24 more
27citations -
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial
Veronica V. Rezelj, Fred Paddenburg, Marie Enajite Diegbe, Julius Nangosyah, Emil Christian Reisinger, Weihong Hu, +8 more
1citations -
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers2025 Therapeutic Advances in Medical Oncology article Medicine Ovarian cancer diagnosis and treatment Open access
Claire Chator, Nozomu Yanaihara, Sylvie Chabaud, Gabriella Maria Parma, Alexandra Lelia Dima, Andrew R. Clamp, +10 more
1citations -
SALVOVAR: A pragmatic randomized phase III trial comparing the salvage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic ovarian cancers (GINECO-OV130b; ENGOT-ov78).
Benoît You, Nozomu Yanaihara, Gabriella Parma, Sylvie Chabaud, L. Del Carpio, Andrew R. Clamp, +10 more
2citations -
Step-in Dosing in the Bosutinib Dose Optimization Study (BODO) Failed to Reduce Gastrointestinal (GI) Toxicity in Patients Failing Second Generation TKI (2G-TKI) in Chronic Phase Chronic Myeloid Leukemia (CML) but Suggests Promising Molecular Response
Susanne Isfort, Dominik Georg Friedrich Wolf, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +11 more
5citations -
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial2020 The Lancet Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access cited by 7 patents
Andrew John Pollard, Odile Launay, Jean‐Daniel Lelièvre, Christine Lacabaratz, Sophie Grande, Neil H. Goldstein, +84 more
173citations -
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory
Chelsea M. McLean, Houreratou Barry, Mark Kieh, Zacchaeus Anywaine, Baimba Rogers, Seydou Doumbia, +21 more
10citations -
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
Susanne Isfort, Kirsi Marjaana Manz, Lino Lars Teichmann, Martina Margrit Crysandt, Andreas Burchert, Andreas Hochhaus, +20 more
17citations -
Repeated versus single praziquantel dosing regimen in treatment of female genital schistosomiasis: a phase 2 randomised controlled trial showing no difference in efficacy2024 Frontiers in Tropical Diseases article Immunology and Microbiology Parasites and Host Interactions Open access
Louise Thomsen Schmidt Arenholt, Bodo Sahondra Randrianasolo, Tiana Onintsoa Oliva Rabozakandraina, Charles Émile Ramarokoto, Karoline Jøker, Katrina Kæstel Aarøe, +13 more
12citations -
A Systematic Evaluation of the Dosing Regimens for Approved Targeted Therapies and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma From a Project OPTIMUS Perspective2025 The Journal of Clinical Pharmacology article Medicine Renal cell carcinoma treatment Open access
Zhiyuan Tan, Swantje Völler, Aymara Sancho‐Araiz, Catherijne A. J. Knibbe, Dirk Jan A. R. Moes
1citations -
Long-term safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen: a cohort study of previously vaccinated adults and children in Sierra Leone (the EBOVAC-Salone extension study)2026 The Lancet Regional Health - Africa article Medicine Viral Infections and Outbreaks Research Open access
Daniela Manno, Ahmed Dahiru Balami, Agnes Bangura, A Kamara, J A Kallon, M L Conteh, +34 more
0citations -
An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial
Jun‐ichi Nishimura, Antoine Soubret, Simon Buatois, Jean‐Eric Charoin, Sasha Sreckovic, Christoph Marcus Bucher, +21 more
3citations -
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial
Etienne Karita, Julien M. Nyombayire, Rosine Ingabire, Amelia Mazzei, Tyronza Sharkey, Jeannine Mukamuyango, +12 more
19citations -
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
Daniela Manno, Catriona Patterson, Abdoulie Drammeh, Kevin K. A. Tetteh, Mattu Tehtor Kroma, Godfrey Tuda Otieno, +20 more
4citations -
Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT2021 Bone Marrow Transplantation article Medicine Hematopoietic Stem Cell Transplantation Open access
Tomasz Czerw, Simona Iacobelli, Vittoria Carolina Malpassuti, Linda Köster, Nicolaus Martin Kröger, Marie Robin, +19 more
14citations -
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo2023 The Journal of Infectious Diseases article Medicine Viral Infections and Outbreaks Research Open access
Ynke Larivière, Irene Garcia-Fogeda, Trésor Zola Matuvanga, Bernard Isekah Osang’ir, Solange Milolo, Rachel Meta, +11 more
9citations -
Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen2024 PLoS neglected tropical diseases article Medicine Viral Infections and Outbreaks Research Open access
Houreratou Barry, Edouard Lhomme, Mathieu Surénaud, Moumini Nouctara, Cynthia Robinson, Viki Bockstal, +7 more
6citations -
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone
Edward Man-Lik Choi, Boris Lacarra, Muhammed Olanrewaju Afolabi, Boni Maxime Ale, Frank Baiden, Christine Bétard, +73 more
18citations